| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/26/2023 | 713.01% | HC Wainwright & Co. | $19 → $10 | Maintains | Buy |
| 08/16/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/20/2021 | 1444.72% | HC Wainwright & Co. | $11 → $19 | Maintains | Buy |
| 05/15/2020 | 794.31% | HC Wainwright & Co. | $7 → $11 | Reiterates | → Buy |
| 02/19/2020 | 1363.41% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
| 12/30/2019 | 469.11% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 09/10/2018 | 3152.03% | Northcoast Research | → $40 | Initiates Coverage On | → Outperform |
| 09/10/2018 | 1769.92% | Laidlaw & Co. | → $23 | Initiates Coverage On | → Buy |
| 09/10/2018 | 1932.52% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
What is the target price for Aridis Pharmaceuticals (ARDS)?
The latest price target for Aridis Pharmaceuticals (NASDAQ: ARDS) was reported by HC Wainwright & Co. on January 26, 2023. The analyst firm set a price target for $10.00 expecting ARDS to rise to within 12 months (a possible 713.01% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aridis Pharmaceuticals (ARDS)?
The latest analyst rating for Aridis Pharmaceuticals (NASDAQ: ARDS) was provided by HC Wainwright & Co., and Aridis Pharmaceuticals maintained their buy rating.
When is the next analyst rating going to be posted or updated for Aridis Pharmaceuticals (ARDS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aridis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aridis Pharmaceuticals was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.
Is the Analyst Rating Aridis Pharmaceuticals (ARDS) correct?
While ratings are subjective and will change, the latest Aridis Pharmaceuticals (ARDS) rating was a maintained with a price target of $19.00 to $10.00. The current price Aridis Pharmaceuticals (ARDS) is trading at is $1.23, which is out of the analyst's predicted range.